Silver Book Fact

Lucentis to treat wet age-related macular degeneration (AMD)

An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.

Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Y. Chung, and Robert Y. Kim. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006; 355(14): 1419-31. http://content.nejm.org/cgi/content/abstract/355/14/1419

Reference

Title
Ranibizumab for Neovascular Age-Related Macular Degeneration
Publication
N Engl J Med
Publication Date
2006
Authors
Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Y. Chung, and Robert Y. Kim
Volume & Issue
Volume 355, Issue 14
Pages
1419-31
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • Between 2008 and 2009, the number of Americans age 65-74 who reported trouble seeing (even with glasses or contacts) decreased from 14.3% to 10.3%.  The number of Americans age 75…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy by 76% in type 1 diabetes patients who had not…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.